Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Its proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. Genocea is conducting a Phase 1/2a clinical trial for GEN-011, an adoptive T cell therapy comprised of neoantigen-targeted peripheral cells. Also, Genocea continues to monitor patients in its Phase 1/2a GEN-009 neoantigen vaccine clinical trial. In addition to the two clinical programs, Genocea is conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases.